NIH-Funded Study Lays Foundation for Antibody-Based Measles Treatment.
Researchers identified the first comprehensive group of human antibodies capable of neutralizing the measles virus, targeting both the hemagglutinin (H) and fusion (F) proteins. Several antibodies demonstrated potent antiviral activity in animal models, with one reducing viral levels to undetectable levels even after exposure. Clinical implications: These findings may support the development of the first antibody-based therapies for measles, particularly for high-risk groups such as immunocompromised patients, pregnant individuals, and infants too young to be vaccinated. Full Access: NIH
FDA Approves AI Sepsis Tool That Detects Infection Hours Earlier Than Doctors
FDA approves a new AI-based sepsis early warning system developed at Johns Hopkins that analyzes electronic health record data to identify patients at risk of sepsis hours before clinical recognition. The tool has been shown to detect sepsis approximately 2–48 hours earlier than standard care and has been associated with reductions in in-hospital mortality and length of stay in prior deployments. By providing “pre-suspicion” alerts, it aims to close the critical treatment gap where delays in recognition significantly worsen outcomes. Clinical implications: This highlights the growing role of predictive AI in early sepsis identification, potentially enabling earlier antibiotics, closer monitoring, and faster escalation of care. However, it also underscores the need for thoughtful integration into workflows to avoid alert fatigue and ensure timely, appropriate clinical response. Full Access: HealthDay
Effectiveness and Tolerability of Pharmacologic Prophylaxis for Chronic Migraine: A Systematic Review of Randomized Controlled Trials
This study shows that overall, preventive treatments significantly reduce monthly migraine and headache days compared with placebo, with the greatest efficacy seen with CGRP-targeting agents and onabotulinumtoxinA, though response varies across drug classes. Tolerability profiles differ, with discontinuation rates influenced by adverse effects such as injection reactions, weight changes, and systemic side effects depending on the medication. Clinical implications: These findings support individualized selection of preventive therapy based on efficacy, comorbidities, side-effect profiles, and patient preferences, rather than a one-size-fits-all approach. The study reinforces early initiation of evidence-based prophylaxis in chronic migraine to reduce disability, improve quality of life, and decrease reliance on acute medications. Full Access: ACP Journal